Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000631560 | SCV000752642 | uncertain significance | Long QT syndrome | 2017-12-24 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with aspartic acid at codon 62 of the KCNH2 protein (p.Gly21Asp). The glycine residue is weakly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. The KCNH2 gene has multiple clinically relevant transcripts. The p.Gly21Asp variant occurs in alternate transcript NM_172057.2, which corresponds to position c.1128+1849G>A in NM_000238.3, the primary transcript listed in the Methods. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly damaging"; Align-GVGD: "Class C0"). This variant has been reported in an individual affected with Long QT syndrome, although a definitive diagnosis was not possible (PMID: 26189708). While this variant is not present in population databases, the frequency information is unreliable, as metrics indicate poor data quality at this position in the ExAC database. |